{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:27:24Z","timestamp":1790040444219,"version":"4.0.1"},"reference-count":72,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs, LLC"},{"name":"Legend Biotech USA, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Although chimeric antigen receptor (CAR)-T cell therapies are typically administered in the inpatient setting, outpatient administration is rapidly expanding. However, there is limited summarized evidence comparing outcomes between outpatient and inpatient administration. This systematic literature review aims to compare the safety, efficacy, quality of life (QoL), costs, and healthcare resource utilization (HCRU) outcomes in patients with hematological cancer who are administered CAR-T therapy in an outpatient versus an inpatient setting. Publications (2016 or later) that reported the outcomes of interest in patients treated with a CAR-T therapy in both outpatient and inpatient settings, or only the outpatient setting, were reviewed. In total, 38 publications based on 21 studies were included. Safety findings suggested the comparable frequency of adverse events in the two settings. Eleven studies that reported data in both settings showed comparable response rates (80\u201382% in outpatient and 72\u201380% in inpatient). Improvements in the QoL were observed in both settings while costs associated with CAR-T therapy were lower in the outpatient setting. Although unplanned hospitalizations were higher in the outpatient cohort, overall HCRU was lower. Outpatient administration of CAR-T therapy appears to have comparable outcomes in safety, efficacy, and QoL to inpatient administration while reducing the economic burden.<\/jats:p>","DOI":"10.3390\/cancers15245746","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:45:33Z","timestamp":1701945933000},"page":"5746","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"first","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Ranjan","sequence":"additional","affiliation":[{"name":"Putnam Associates, Gurgaon 122002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Putnam Associates, Gurgaon 122002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[{"name":"Putnam Associates, New York, NY 10282, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"McFarland","sequence":"additional","affiliation":[{"name":"Legend Biotech USA, Inc., Piscataway, NJ 08854, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[{"name":"Janssen Biotech, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Huo","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1612702","DOI":"10.1155\/2022\/1612702","article-title":"The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030","volume":"2022","author":"Du","year":"2022","journal-title":"J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1038\/bcj.2015.29","article-title":"Haematological cancer and quality of life: A systematic literature review","volume":"5","author":"Porro","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1745017902016010174","article-title":"Health Related Quality of Life in Patients with Onco-hematological Diseases","volume":"16","author":"Caocci","year":"2020","journal-title":"Clin. Pract. Epidemiol. Ment. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S2352-3026(16)30062-X","article-title":"Economic burden of malignant blood disorders across Europe: A population-based cost analysis","volume":"3","author":"Burns","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1007\/s12325-021-01872-x","article-title":"Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies","volume":"38","author":"Yucel","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0106wik\u0142a, A., M\u0105czy\u0144ski, M., and Regiec, A. (2021). FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review. Cancers, 14.","DOI":"10.3390\/cancers14010087"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lei, W., Xie, M., Jiang, Q., Xu, N., Li, P., Liang, A., Young, K.H., and Qian, W. (2021). Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13153912"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","unstructured":"(2023, July 18). Chimeric Antigen Receptor CAR T Cell Therapy Cancer Treatment Market Size Report. Available online: https:\/\/www.globenewswire.com\/news-release\/2022\/06\/25\/2469076\/0\/en\/Chimeric-Antigen-Receptor-CAR-T-Cell-Therapy-Cancer-Treatment-Market-Size-Report.html."},{"key":"ref_12","unstructured":"(2023, July 18). Facts about Chimeric Antigen Receptor (CAR) T-Cell Therapy. Available online: https:\/\/www.lls.org\/sites\/default\/files\/2021-05\/FSHP1_CART_Factsheet_Sept2020_Rev.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Barros, L.R.C., Couto, S.C.F., da Silva Santurio, D., Paix\u00e3o, E.A., Cardoso, F., da Silva, V.J., Klinger, P., Ribeiro, P., R\u00f3s, F.A., and Oliveira, T.G.M. (2022). Systematic Review of Available CAR-T Cell Trials around the World. Cancers, 14.","DOI":"10.3390\/cancers14112667"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29843","DOI":"10.18632\/oncotarget.25688","article-title":"CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e005145","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2019.12.093","article-title":"Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed\/Refractory (R\/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT","volume":"26","author":"Bachier","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood-2018-99-115252","article-title":"Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10428194.2022.2147395","article-title":"Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy\u2013a retrospective cohort study using CMS 100% Medicare claims database","volume":"64","author":"Yang","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_28","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2022). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022), Cochrane. Available online: www.training.cochrane.org\/handbook."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_31","unstructured":"(2023, July 18). Newcastle-Ottawa Quality Assessment form for Cohort and Case-Control Studies. Available online: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/nosgen.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/S2666-6367(21)00251-7","article-title":"Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"27","author":"Godwin","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-136640","article-title":"Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study","volume":"136","author":"Godwin","year":"2020","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/hon.185_2880","article-title":"Outreach: Preliminary safety & efficacy results from a phase 2 study of lisocabtagene maraleucel (LISO-CEL) in the nonuniversity setting","volume":"39","author":"Godwin","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e19513","DOI":"10.1200\/JCO.2021.39.15_suppl.e19513","article-title":"Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the non university setting","volume":"39","author":"Godwin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2021-148792","article-title":"Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R\/R Large B-Cell Lymphoma (LBCL)","volume":"138","author":"Godwin","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10416","DOI":"10.1182\/blood-2022-159595","article-title":"Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community\/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"140","author":"Linhares","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10930","DOI":"10.1182\/blood-2022-159645","article-title":"Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community\/Nonuniversity Setting: Patient-Reported Outcomes\/Health-Related Quality of Life from the Outreach Study","volume":"140","author":"Linhares","year":"2022","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2019-127658","article-title":"Lisocabtagene maraleucel (liso-cel) for treatment of second-line transplant noneligible (TNE) relapsed\/refractory (R\/R) aggressive non-hodgkin lymphoma (NHL): Initial results from the PILOT Study","volume":"134","author":"Sehgal","year":"2019","journal-title":"Blood"},{"key":"ref_41","first-page":"S32","article-title":"Post-infusion monitoring costs by site of care among patients with relapsed or refractory large B-cell lymphoma who received second-line treatment with lisocabtagene maraleucel in the PILOT study","volume":"28","author":"McGarvey","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_43","first-page":"1552","article-title":"Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed\/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration","volume":"130","author":"Maloney","year":"2017","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1182\/blood-2018-99-119387","article-title":"TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"132","author":"Palomba","year":"2018","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.bbmt.2019.12.695","article-title":"Inpatient and intensive care unit resource utilization after CD19-targeted chimeric antigen receptor T-cell therapy (CART19) for pediatric acute lymphoblastic leukemia (ALL)","volume":"26","author":"Myers","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2021-149181","article-title":"Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed\/Refractory B-NHL and CLL","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-136440","article-title":"Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"136","author":"Shadman","year":"2020","journal-title":"Blood"},{"key":"ref_49","first-page":"335","article-title":"Immunotherapy Using a 3rd Generation CD20 Targeted CAR T-Cell (MB-106) for Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia (CLL)","volume":"5","author":"Shadman","year":"2021","journal-title":"HemaSphere"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.HS9.0000843720.23634.a9","article-title":"Efficacy and safety of a third generation CD20 CART (MB-106) for treatment of Relapsed\/Refractory Follicular Lymphoma (FL)","volume":"6","author":"Shadman","year":"2022","journal-title":"HemaSphere"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2017.35.15_suppl.3020","article-title":"Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor-(CAR-) modified T cells","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-141415","article-title":"Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1016\/S2152-2650(22)01544-0","article-title":"ABCL-509 Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma","volume":"22","author":"Denlinger","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2022-163678","article-title":"Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in US","volume":"140","author":"Chihara","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: Experience from a tertiary care center","volume":"57","author":"Borogovac","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/blood-2021-153457","article-title":"Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program","volume":"138","author":"Borogovac","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1182\/blood-2021-146283","article-title":"Feasibility of Outpatient CAR T Cell Therapy: Experience of a Single Institution","volume":"138","author":"Shao","year":"2021","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e19550","DOI":"10.1200\/JCO.2021.39.15_suppl.e19550","article-title":"Healthcare resource use (HRU) by infusion setting of chimeric antigen receptor T-cell (CAR-T) in patients with relapsed and refractory (r\/r) diffuse large B-cell lymphoma (DLBCL): A retrospective cohort study using CMS 100% Medicare database","volume":"39","author":"Zhao","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1016\/j.clml.2022.04.012","article-title":"Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting","volume":"22","author":"Nasta","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_61","first-page":"S37","article-title":"Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: An analysis of hospital data","volume":"27","author":"Maziarz","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1080\/10428194.2022.2060503","article-title":"Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: An analysis of hospital data in the United States","volume":"63","author":"Maziarz","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10812","DOI":"10.1182\/blood-2022-168207","article-title":"Successful Outpatient Treatment and Monitoring Following Administration of Various Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas","volume":"140","author":"Kirby","year":"2022","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_65","first-page":"S33","article-title":"Post-infusion monitoring costs by site of care among patients with relapsed or refractory large B-cell lymphoma who received second-line treatment with lisocabtagene maraleucel in the TRANSFORM study","volume":"28","author":"McGarvey","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2021-145741","article-title":"Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study","volume":"138","author":"Fowler","year":"2021","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"60.e61","DOI":"10.1016\/j.jtct.2022.09.022","article-title":"Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study","volume":"29","author":"Fowler","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1016\/j.ijrobp.2020.02.590","article-title":"Impact of Radiotherapy on Hospitalization Burden Surrounding Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_69","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014A primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1007\/s11136-020-02602-6","article-title":"Quality of life and distress assessed with self and external assessment screening tools in patients with hematologic malignancies attending treatment in an acute hospital","volume":"29","author":"Senf","year":"2020","journal-title":"Qual. Life Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejon.2008.03.004","article-title":"Preferences for involvement in treatment decision making of patients with cancer: A review of the literature","volume":"12","author":"Hubbard","year":"2008","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients with Relapsed or Refractory Large B-Cell Lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw. Open"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5746\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:54Z","timestamp":1760132094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":72,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245746"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245746","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}